Benco Dental recently signed a cooperative agreement with Vivos Therapeutics, a company that focuses on addressing the causes of mild to moderate obstructive sleep apnea (OSA).
The alliance will allow Vivos to introduce more dentists to the Vivo System, which is a non-invasive, non-surgical, non-pharmaceutical, multidisciplinary treatment modality for mild to moderate OSA that does not require lifetime care for most patients, according to a press release.
The proprietary Vivos System enhances and increases the upper airway and offers patients what is believed to be the “first truly effective non-surgical, non-invasive and potentially lasting solution.” Clinical results are typically achieved in 18 to 24 months or less.
The partnership will launch with a series of events set to begin in October. The companies also plan to complete 27 seminars during the first quarter of 2020. Benco customers in all 50 states will have the chance to learn more about the treatment, how it helps OSA patients and how it creates value for dental practices.
View Full Press Release